Literature DB >> 30565146

The Hippo Signaling Pathway in Regenerative Medicine.

Lixin Hong1, Yuxi Li1, Qingxu Liu1, Qinghua Chen1, Lanfen Chen1, Dawang Zhou2.   

Abstract

The major role of Hippo signaling is to inhibit their downstream effectors YAP/TAZ for organ size control during development and regeneration (Nat Rev Drug Discov 13(1):63-79, 2014; Dev Cell 19(4):491-505, 2010; Cell 163(4):811-828, 2015). We and others have demonstrated that the genetic disruption of kinases Mst1 and Mst2 (Mst1/2), the core components of Hippo signaling, results in YAP activation and sustained liver growth, thereby leading to an eight- to tenfold increase in liver size within 3 months and occurrence of liver cancer within 5 months (Curr Biol 17(23):2054-2060, 2007; Cancer Cell 16(5):425-438, 2009; Cell 130(6):1120-1133, 2007; Cancer Cell 31(5):669-684 e667, 2017; Nat Commun 6:6239, 2015; Cell Rep 3(5):1663-1677, 2013). XMU-MP-1, an Mst1/2 inhibitor, is able to augment mouse liver and intestinal repair and regeneration in both acute and chronic injury mouse models (Sci Transl Med 8:352ra108, 2016).In addition, YAP-deficient mice show an impaired intestinal regenerative response after DSS treatment or gamma irradiation (Proc Natl Acad Sci U S A 108(49):E1312-1320, 2011; Nature 493(7430):106-110, 2013; Genes Dev 24(21):2383-2388, 2010; J Vis Exp (111), 2010). IBS008738, a TAZ activator, facilitates muscle repair after cardiotoxin-induced muscle injury (Mol Cell Biol. 2014;34(9):1607-21). Deletion of Salvador (Sav) in mouse hearts enhances cardiomyocyte regeneration with reduced fibrosis and recovery of pumping function after myocardial infarction (MI) or resection of mouse cardiac apex (Development 140(23):4683-4690, 2013; Sci Signal 8(375):ra41, 2015; Nature 550(7675):260-264, 2017). This chapter provides a detailed description of procedures and important considerations when performing the protocols for the respective assays used to determine the effects of Hippo signaling on tissue repair and regeneration.

Entities:  

Keywords:  Hippo signaling; Protocol; Tissue regeneration

Mesh:

Substances:

Year:  2019        PMID: 30565146     DOI: 10.1007/978-1-4939-8910-2_26

Source DB:  PubMed          Journal:  Methods Mol Biol        ISSN: 1064-3745


  5 in total

1.  Exploring the influence of cytosolic and membrane FAK activation on YAP/TAZ nuclear translocation.

Authors:  Kerbaï Saïd Eroumé; Rachel Cavill; Katerina Staňková; Jan de Boer; Aurélie Carlier
Journal:  Biophys J       Date:  2021-09-10       Impact factor: 3.699

2.  Silencing SAPCD2 Represses Proliferation and Lung Metastasis of Fibrosarcoma by Activating Hippo Signaling Pathway.

Authors:  Bowen Zhu; Yanqin Wu; Lizhi Niu; Wang Yao; Miao Xue; Hongyu Wang; Jianyong Yang; Jiaping Li; Wenzhe Fan
Journal:  Front Oncol       Date:  2020-12-15       Impact factor: 6.244

Review 3.  Recent Therapeutic Approaches to Modulate the Hippo Pathway in Oncology and Regenerative Medicine.

Authors:  Evan R Barry; Vladimir Simov; Iris Valtingojer; Olivier Venier
Journal:  Cells       Date:  2021-10-11       Impact factor: 6.600

4.  Activated TAZ induces liver cancer in collaboration with EGFR/HER2 signaling pathways.

Authors:  Hyuk Moon; Hyunjung Park; Min Jee Chae; Hye Jin Choi; Do Young Kim; Simon Weonsang Ro
Journal:  BMC Cancer       Date:  2022-04-19       Impact factor: 4.638

Review 5.  High Risk of Hepatocellular Carcinoma Development in Fibrotic Liver: Role of the Hippo-YAP/TAZ Signaling Pathway.

Authors:  Hyuk Moon; Kyungjoo Cho; Sunyeong Shin; Do Young Kim; Kwang-Hyub Han; Simon Weonsang Ro
Journal:  Int J Mol Sci       Date:  2019-01-29       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.